Edinburgh: December 2014
NuCana appoints Dr. Paolo Paoletti to its board of Directors.
Chicago: May 2014
Acelarin achieves high disease control rate in patients with advanced cancer. ProGem1 study results presented at the ASCO 50th Annual Meeting.
Edinburgh: April 2014
NuCana announces a Series B financing of $57 million to fund expansion of clinical studies with its anti-cancer ProTides.